Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1472

1.

In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.

Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.

J Immunother. 2007 Nov-Dec;30(8):789-97.

PMID:
18049330
2.

Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.

Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR.

Exp Hematol. 2006 Oct;34(10):1403-12.

PMID:
16982333
4.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
5.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
6.

Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.

Song S, Wang Y, Zhang Y, Wang F, He Y, Ren D, Guo Y, Sun S.

Cancer Lett. 2007 Oct 18;256(1):90-100.

PMID:
17656012
7.
8.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

9.

Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.

Wu YG, Wu GZ, Wang L, Zhang YY, Li Z, Li DC.

Med Oncol. 2010 Sep;27(3):736-42. doi: 10.1007/s12032-009-9277-x.

PMID:
19669608
10.

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.

Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.

Cancer Res. 2004 Jul 15;64(14):4973-9.

11.

An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.

Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.

Int Immunol. 2006 Mar;18(3):425-34.

12.
14.

Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.

Bae SM, Kim YW, Kwak SY, Kim YW, Ro DY, Shin JC, Park CH, Han SJ, Oh CH, Kim CK, Ahn WS.

Cancer Sci. 2007 May;98(5):747-52.

15.

Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.

Gatza E, Okada CY.

J Immunol. 2002 Nov 1;169(9):5227-35. Erratum in: J Immunol. 2003 May 15;170(10):following 5332.

16.
17.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008.

PMID:
19664962
19.

Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.

Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.

Cancer Res. 2001 Oct 15;61(20):7563-7.

20.

Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.

Kim CH, Hong MJ, Park SD, Kim CK, Park MY, Sohn HJ, Cho HI, Kim TG, Hong YK.

Cancer Immunol Immunother. 2006 Nov;55(11):1309-19.

PMID:
16463038
Items per page

Supplemental Content

Support Center